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whereas in the small cell lung cancer group 6 out of the total of 17 
(35.29%) developed brain metastases. The development of brain 
metastases in non small cell lung cancer was however independent of 
the initial stage of the disease, primary treatment received and the time 
elapsed between diagnosis and treatment.
Conclusion: PCI is recommended treatment for limited disease SCLC 
patients. Despite the observed phenomenon of potentially increasing 
numbers of patients with relapse in the brain as a ‘sanctuary site’, our 
data almost concurs with national ﬁgures suggesting that brain metas-
tases are three times more common in SCLC compared to NSCLC. We 
did not ﬁnd any risk factors that predicted development of brain me-
tastases in patients receiving radical treatment. In the case of NSCLC, 
this review highlights that brain metastases occurred independently of 
disease stage and response to treatment, making it difﬁcult to individu-
alise patients who would beneﬁt from PCI. We therefore feel that the 
current practice of not giving PCI to patients with Non small cell lung 
cancer is the best approach
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Background: Approximately 1 in 4 patients with NSCLC will develop 
brain metastases. For many years the standard therapy for patients with 
inoperable brain metastases has remained a combination of steroids 
and whole brain radiotherapy (WBRT). However, WBRT causes side 
effects and has never been shown to correlate with an improved quality 
or length of survival. In view of the fact that the median survival from 
diagnosis of brain metastases is only approximately 3 months, a large 
randomised trial is required to determine whether WBRT provides 
improved survival, function and/or enhances quality of life for these 
patients.
Methods: The QUARTz trial will compare Optimal Supportive Care 
(OSC, including dexamethasone) with OSC (including dexamethasone) 
and WBRT (20Gy in 5f) in the treatment of patients with inoperable 
brain metastases from NSCLC. The trial has been designed to be very 
pragmatic. Thus if a clinician is certain that WBRT will or will not be 
of beneﬁt for a speciﬁc patient, QUARTz should not be considered. 
However, if the clinician is uncertain that WBRT is the way forward, 
QUARTz is an opportunity to address that uncertainty. The primary 
endpoint will be quality adjusted life years (QALYs), the aim of which 
is to combine duration and quality of life in one measure. As many 
of these patients will be too ill to travel to hospital on a regular basis, 
information on each patient’s well-being will be collected via a weekly 
telephone assessment. A questionnaire including the EQ-5D and a list 
of symptoms will be used. Data from the EQ-5D will be combined with 
duration of survival to calculate each patient’s QALY. QUARTz has 
been designed as a non-inferiority trial on the basis that a >20% relative 
decrease in QALYs with OSC alone would be clinically unacceptable. 
Therefore a total of at least 1000 patients will be required to reliably 
exclude such a difference (80% power, 1-sided alpha of p=0.025). 
The effect of terminal cancer on patients’ carers is an under-researched 
area. The QUARTz trial will attempt to address this issue, by also 
collecting information on carers concerns via a weekly telephone call 
using the Carer Concerns Checklist.
Conclusions: QUARTz will produce robust evidence for the inclu-
sion or otherwise of WBRT in the routine management of patients 
with NSCLC and non-resectable brain metastases. Furthermore this 
large, pragmatic, international trial may lead to developments in other 
disease areas, as approximately 20-40% of all cancer patients develop 
brain metastases. The trial is now actively recruiting in the UK (MRC), 
Australia and New Zealand (TROG), and discussions with other groups 
are ongoing. 
See also: Bezjak A, et al. Eur J Ca 2002, 38, 487-496, Gerrard G, et al. 
Clin Onc 2003, 15, 422-428, Hoskin PJ. Clin Onc 2003, 15, 420-421, 
Tsao MN, et al. Clin Onc 2003, 15, 429-434, Khanduri S, et al. Clin 
Onc 2006, 18, 744-746, Editorial. Lancet Oncol 2006, 7, 189, Nelson 
R. Lancet Oncol 2006, 7, 205-296
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The Nordic experience with SBRT for medically inoperable stage I 
NSCLC, based on a retrospective analysis of 138 inoperable patients 
treated during 1996-2003, showed an impressing overall response rate 
(CR, PR) of 61%, a local control rate of 88%, and the 3- and 5-year 
overall survival was 52 and 26% respectively. The lung cancer speciﬁc 
3- and 5-year overall survival was 66 and 40% respectively (Baumann 
P. et al. Acta Oncol. 2006;45(7):787-95). We have now performed a 
GCP controlled phase II study on the same category of pats.(60 cases 
from 7 different centres in Sweden, Norway and Denmark) with inclu-
sion Aug.2003 - Sept.2005. Median age was 76 years (range 58-87 y) 
with 28 males and 32 women. Mean FEV1 at start was 59 %. Mean 
karnofsky index before treatment was 82. Sixty-ﬁve % were T1 and 
35% T2 tumors. Mean tumor diam. was 25 mm (6-49). Mean tumors 
vol. was 16 cc (1-51). The tumours were morphologically veriﬁed in 
70% of the cases, 17% squamous cell carcinoma, 33% adenocarcinoma 
and 20% unspeciﬁed NSCLC. The patients were considered inoperable 
mainly because of COPD or CVD. Four patients refused surgery.
Treatment: SBRT was delivered after immobilizing the patients in a 
stereotactic body frame (SBF). A 3D conformal multiﬁeld technique 
was used. The patients were treated with a dose of 15 Gy x 3 (BED 112 
Gy) with the 65% isodose to the periphery of the PTV. Mean volumes 
of GTV and PTV were 17 cc and 72 cc, and the mean dose to GTV was 
65 Gy. To the ipsilateral lung, excluding the GTV, the mean dose was 
7.4 Gy. All patients were planned with pencil beam algorithms in the 
Helax-TMS or Eclipse systems, which both overestimate the dose in 
the volume between the GTV and PTV. Data from Monte-Carlo simula-
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tion of dose distributions in lung tumours have been used to correct 
DVH’s planned in a static situation with pencil beam to a dynamic situ-
ation, considering breathing motions and a more correct dose calcula-
tion.
Results: At 17 mo. after end of study there is one local relapse alone 
and 7 cases displaying distant metastasis of which 2 are combined with 
regional failure (1 T1 and 6 T2). Grade 3 toxicity was seen in 3 patients 
with dyspnoe at 3, 6 and 9 months, not correlated with pneumonitis or 
ﬁbrosis. Spirometry data will be reported. Grade 3 toxicity with pain in 
the thorax was seen in 2 patients at 9 and 12 months not associated with 
rib fracture or tumor in proximity to the thoracic wall. 13/59 (22%) did 
not have any side effects. The most common side effect at 6 weeks was 
grade I skin reactions (19 patients with grade I and 4 with grade 2). At 
17 mo. after end of study 11 pts. had obtained CR, 30 showed PR and 8 
pats. had either local failure and/or distant metastases.
Conclusion: Using 15 x 3 Gy to stage I NSCLC results in acceptable 
early toxicity and favourable local control rate non inferior to what has 
been reported with fractionated RT.
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Background: For stereotactic lung irradiation, the dose is frequently 
prescribed to an isodose surface that encompasses the Planning Target 
Volume (PTV). This method is sensitive to incorrect modeling of the 
beam penumbra. Most dose calculation algorithms present in commer-
cially available treatment planning systems model the beam penumbra 
in water correctly. However, the beam penumbra in lung is much wider 
due to radiation and particle transport effects in low-density tissue, and 
is approximated only to a reasonable accuracy by few of the available 
calculation algorithms.
The aim of this study is to determine the effect of two dose calculation 
methods, with and without heterogeneity correction, on the prescribed 
dose to the tumor and the dose distribution in surrounding tissue. 
Methods: In our institute, stereotactic treatment plans for lung consist 
of 10 - 20 non-opposing photon beams (maximum energy 10 MV). 
Beam shapes and weights are optimized using Direct Machine Param-
eter Optimization (DMPO) available in the Pinnacle treatment planning 
system. A dose of 3 x 18 Gy is prescribed on the isodose surface that 
encompasses 95% of the PTV. Dose calculation is performed using 
the collapsed cone convolution/superposition algorithm, including all 
effects of tissue heterogeneity (heterogeneous plan). This algorithm is 
proven to be accurate in the presence of tissue heterogeneities through 
measurements in phantoms and comparison with Monte Carlo simula-
tions. To simulate an inaccurate dose calculation, we recalculated for 
15 patients the clinical treatment plan without heterogeneity corrections 
(homogeneous plan) while maintaining the number of Monitor Units 
(MU) from the clinical plan. The following dose parameters were com-
pared between the two plans: absolute isodose surface encompassing 
95% of the PTV (Dpres), relative maximum dose in the PTV (Dmax), 
ratio of the 50% prescription isodose volume to the PTV (R50), maxi-
mum dose 2 cm from PTV (D2cm), and percentage of lung volume 
receiving 20 Gy or more (V20).
Results: Compared to the heterogoneous plan, Dpres of the homoge-
neous plan increased from 54 Gy (by deﬁnition) to an average of 59 ± 
4 Gy (range 54 to 67 Gy). Due to increased attenuation and tightening 
of the beam penumbra in the homogeneous plan, Dmax was lower for 
the homogeneous plans (average 124% vs. 132%), while dose fall-off 
outside the PTV was steeper. The latter is reﬂected in a lower R50 for 
the homogeneous plans (4.2 ± 0.8) than for the heterogeneous plan (4.9 
± 1). D2cm and V20 were comparable for the two calculation methods 
(29 ± 2 Gy and 5 ± 2 %, respectively).
Conclusions: The absence of any heterogeneity correction (as required 
by some trial protocols) results in profound errors in dose distributions 
and the prescribed dose of stereotactic lung irradiation. Any dose calcu-
lation algorithm that does not predict penumbra broadening accurately 
(e.g. pencil beam algorithms), will result in errors in the calculated dose 
distributions which will affect the dose. The quality of the dose calcula-
tion algorithm is therefore an important parameter when comparing the 
local control and toxicity results of stereotactic studies in lung.
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Purpose: Assess the outcomes of non-small cell lung cancer (NSCLC) 
patients presenting with brain metastases (BM). 
Background: The brain is a common site of metastases and fre-
quently the ﬁrst site of treatment failure in non-small cell lung cancer 
(NSCLC). Patents presenting with synchronous BM may represent 
a unique population that could potentially beneﬁt from aggressive 
therapy. At this time, generally accepted treatment guidelines have not 
been established for these patients. 
Methods: Retrospective review of patients presenting with NSCLC 
with synchronous BM. Patients were assessed regarding treatment for 
both intracranial and intrathoracic disease. Aggressive treatment to 
the brain included either craniotomy or gamma knife radiosurgery and 
aggressive treatment to the primary lung cancer consisted of surgery, 
chemoradiation therapy or both.
Results: 75 NSCLC patients presented with synchronous BM treated 
between 1998-2002. 34 M: 41F, median age 60 years (40 -85), and 
median Karnofsky score 79 (40 - 100). Sixty-percent (45 pts) had 
extracranial metastases at the time of diagnosis, and 36 patients (48%) 
had a single brain metastasis. Treatment was considered aggressive 
(e.g. craniotomy or Gamma Knife radiosurgery) for CNS disease 43 
patients and for chest disease (e.g. surgery or chemoradiotherapy) in 
20 patients. With a median follow-up was 15 months (1-107), me-
dian survival was 8.4 months in the aggressive treatment group and 
7.7months in the “palliative” treatment group (p= 0.44). Ten patients 
survived more than 2 years (median 48 months for this cohort), and 
9/10 received aggressive CNS treatment while 5/10 recieved aggressive 
intrathoracic treatment. The patterns of relapse were similar in the ag-
gressive and palliative treatment groups. Twenty one patients recurred 
in the brain, (10/43 in aggressive treatment group, 11/36 palliative 
group). 9 patients recurred or demonstrated progressive disease in the 
lung (1/12 aggressive treatment group, 8/63 in non-aggressive group). 
In an analysis of prognostic factors including performance status, 
